Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia
- 23 May 2013
- journal article
- Published by American Society of Hematology in Blood
- Vol. 121 (21) , 4348-4354
Abstract
We report preclinical proof of principle for effective treatment of B-precursor acute lymphoblastic leukemia (ALL) by targeting the spleen tyrosine kinase (SYK)–dependent antiapoptotic blast cell survival machinery with a unique nanoscale pharmaceutical composition. This nanoscale liposomal formulation (NLF) contains the pentapeptide mimic 1,4-Bis (9-O dihydroquinidinyl) phthalazine/hydroquinidine 1,4-phathalazinediyl diether (C61) as the first and only selective inhibitor of the substrate binding P-site of SYK. The C61 NLF exhibited a very favorable pharmacokinetic and safety profile in mice, induced apoptosis in primary B-precursor ALL blast cells taken directly from patients as well as in vivo clonogenic ALL xenograft cells, destroyed the in vivo clonogenic fraction of ALL blast cells, and, at nontoxic dose levels, exhibited potent in vivo antileukemic activity against patient-derived ALL cells in xenograft models of aggressive B-precursor ALL. Our findings establish SYK as an attractive molecular target for therapy of B-precursor ALL. Further development of the C61 NLF may provide the foundation for therapeutic innovation against therapy-refractory B-precursor ALL. Key Points SYK is a suitable molecular target for nanotechnology-enabled therapy against ALL. Nanoscale liposomal formulation of SYK inhibitor C61 displayed a promising preclinical profile as an antileukemic drug candidate.Keywords
This publication has 21 references indexed in Scilit:
- Protein kinase inhibitors against malignant lymphomaExpert Opinion on Pharmacotherapy, 2013
- Revival of the abandoned therapeutic wortmannin by nanoparticle drug deliveryProceedings of the National Academy of Sciences, 2012
- Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An UpdateJournal of Clinical Oncology, 2011
- Targeting SYK kinase-dependent anti-apoptotic resistance pathway in B-lineage acute lymphoblastic leukaemia (ALL) cells with a potent SYK inhibitory pentapeptide mimicBritish Journal of Haematology, 2010
- STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stressProceedings of the National Academy of Sciences, 2010
- Therapeutic prospect of Syk inhibitorsExpert Opinion on Therapeutic Patents, 2009
- Protein kinase inhibitors: contributions from structure to clinical compoundsQuarterly Reviews of Biophysics, 2009
- In Childhood Acute Lymphoblastic Leukemia, Blasts at Different Stages of Immunophenotypic Maturation Have Stem Cell PropertiesCancer Cell, 2008
- Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology GroupBlood, 2008
- Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemiaOncogene, 2001